ID   FGFR4_HUMAN             Reviewed;         802 AA.
AC   P22455; G3JVM2; G3JVM5; G3JVM7; G3JVM9; O43785; Q14309; Q71TW8;
AC   Q8TDA0; Q96KE5;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   27-APR-2001, sequence version 2.
DT   10-MAY-2017, entry version 193.
DE   RecName: Full=Fibroblast growth factor receptor 4;
DE            Short=FGFR-4;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD334;
DE   Flags: Precursor;
GN   Name=FGFR4; Synonyms=JTK2, TKF;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1709094;
RA   Partanen J.M., Maekelae T.P., Eerola E., Korhonen J., Hirvonen H.,
RA   Claesson-Welsh L., Alitalo K.;
RT   "FGFR-4, a novel acidic fibroblast growth factor receptor with a
RT   distinct expression pattern.";
RL   EMBO J. 10:1347-1354(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION AS RECEPTOR FOR
RP   FGF1 AND FGF2.
RC   TISSUE=Mammary gland;
RX   PubMed=7680645;
RA   Ron D., Reich R., Chedid M., Lengel C., Cohen O.E., Chan A.M.,
RA   Neufeld G., Miki T., Tronick S.R.;
RT   "Fibroblast growth factor receptor 4 is a high affinity receptor for
RT   both acidic and basic fibroblast growth factor but not for
RT   keratinocyte growth factor.";
RL   J. Biol. Chem. 268:5388-5394(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT LEU-136, TISSUE
RP   SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Intestine;
RX   PubMed=10631118; DOI=10.1006/bbrc.1999.2010;
RA   Takaishi S., Sawada M., Morita Y., Seno H., Fukuzawa H., Chiba T.;
RT   "Identification of a novel alternative splicing of human FGF receptor
RT   4: soluble-form splice variant expressed in human gastrointestinal
RT   epithelial cells.";
RL   Biochem. Biophys. Res. Commun. 267:658-662(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9457674; DOI=10.1007/s003359900703;
RA   Kostrzewa M., Muller U.;
RT   "Genomic structure and complete sequence of the human FGFR4 gene.";
RL   Mamm. Genome 9:131-135(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), SUBCELLULAR LOCATION (ISOFORM
RP   3), INVOLVEMENT IN CANCER, AND VARIANT PC ARG-388.
RC   TISSUE=Pituitary;
RX   PubMed=11781352; DOI=10.1172/JCI14036;
RA   Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L.;
RT   "Targeted expression of a human pituitary tumor-derived isoform of FGF
RT   receptor-4 recapitulates pituitary tumorigenesis.";
RL   J. Clin. Invest. 109:69-78(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANTS ILE-10 AND LEU-136,
RP   INVOLVEMENT IN CANCER, AND VARIANT PC ARG-388.
RX   PubMed=21882254; DOI=10.1002/mc.20848;
RA   Marshall A.D., van der Ent M.A., Grosveld G.C.;
RT   "PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma.";
RL   Mol. Carcinog. 51:807-815(2012).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LEU-136.
RA   Lind D.L., Cox D.R.;
RT   "Sequence variation in fibroblast growth factor receptors 3 and 4.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-10; LEU-136 AND
RP   ARG-388.
RG   NIEHS SNPs program;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-136.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 609-676.
RC   TISSUE=Blood;
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [13]
RP   PROTEIN SEQUENCE OF 22-38.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [14]
RP   FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF SIGNALING VIA PLCG1 AND
RP   PIK3R1, INTERACTION WITH PLCG1, PHOSPHORYLATION AT TYR-754, AND
RP   MUTAGENESIS OF TYR-754.
RX   PubMed=7518429;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G.,
RA   Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [15]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF6; FGF8 AND FGF9, AND FUNCTION
RP   IN CELL PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [16]
RP   FUNCTION IN CELL DIFFERENTIATION, MUTAGENESIS OF LYS-503, CATALYTIC
RP   ACTIVITY, AND IDENTIFICATION IN A COMPLEX WITH NCAM1; CDH2; PLCG1;
RP   FRS2; SRC; SHC; GAP43 AND CTTN.
RX   PubMed=11433297; DOI=10.1038/35083041;
RA   Cavallaro U., Niedermeyer J., Fuxa M., Christofori G.;
RT   "N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-
RT   receptor signalling.";
RL   Nat. Cell Biol. 3:650-657(2001).
RN   [17]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=11830541;
RA   Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M.,
RA   Knyazeva T., Mueller S., Gaertner S., Sures I., Wang H., Imyanitov E.,
RA   Haering H.U., Knayzev P., Iacobelli S., Hoefler H., Ullrich A.;
RT   "Cancer progression and tumor cell motility are associated with the
RT   FGFR4 Arg(388) allele.";
RL   Cancer Res. 62:840-847(2002).
RN   [18]
RP   INTERACTION WITH FGF1; FGF17; FGF18; FGF19; FGF21 AND FGF23, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [19]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN SIGNALING AND
RP   IN REGULATION OF CYP7A1 AND BILE ACID SYNTHESIS.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [20]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   LYS-503, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [21]
RP   INVOLVEMENT IN PC, AND VARIANT PC ARG-388.
RX   PubMed=18756523; DOI=10.1002/ijc.23578;
RA   Ma Z., Tsuchiya N., Yuasa T., Inoue T., Kumazawa T., Narita S.,
RA   Horikawa Y., Tsuruta H., Obara T., Saito M., Satoh S., Ogawa O.,
RA   Habuchi T.;
RT   "Polymorphisms of fibroblast growth factor receptor 4 have association
RT   with the development of prostate cancer and benign prostatic
RT   hyperplasia and the progression of prostate cancer in a Japanese
RT   population.";
RL   Int. J. Cancer 123:2574-2579(2008).
RN   [22]
RP   CATALYTIC ACTIVITY, FUNCTION AS FGF1 RECEPTOR AND IN ACTIVATION OF
RP   PLCG1; FRS2; MAPK1/ERK2 AND MAPK3/ERK1, ENZYME REGULATION,
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=18480409; DOI=10.1091/mbc.E07-12-1219;
RA   Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J.;
RT   "Ubiquitination of fibroblast growth factor receptor 1 is required for
RT   its intracellular sorting but not for its endocytosis.";
RL   Mol. Biol. Cell 19:3390-3403(2008).
RN   [23]
RP   CATALYTIC ACTIVITY, FUNCTION AS FGF2 RECEPTOR AND IN STIMULATION OF
RP   CELL PROLIFERATION, SUBCELLULAR LOCATION, INTERACTION WITH FGF2 AND
RP   HIP1, PHOSPHORYLATION AT TYR-642 AND TYR-643, INVOLVEMENT IN PC, AND
RP   CHARACTERIZATION OF VARIANT PC ARG-388.
RX   PubMed=18670643; DOI=10.1593/neo.08450;
RA   Wang J., Yu W., Cai Y., Ren C., Ittmann M.M.;
RT   "Altered fibroblast growth factor receptor 4 stability promotes
RT   prostate cancer progression.";
RL   Neoplasia 10:847-856(2008).
RN   [24]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=20638838; DOI=10.1016/j.ejca.2010.06.017;
RA   Xu W., Li Y., Wang X., Chen B., Wang Y., Liu S., Xu J., Zhao W.,
RA   Wu J.;
RT   "FGFR4 transmembrane domain polymorphism and cancer risk: a meta-
RT   analysis including 8555 subjects.";
RL   Eur. J. Cancer 46:3332-3338(2010).
RN   [25]
RP   FUNCTION IN FGF19 SIGNALING AND IN REGULATION OF BILE ACID SYNTHESIS
RP   VIA CYP7A1, INTERACTION WITH FGF19; KL AND KLB, AUTOPHOSPHORYLATION,
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=20683963; DOI=10.1002/hep.23708;
RA   Triantis V., Saeland E., Bijl N., Oude-Elferink R.P., Jansen P.L.;
RT   "Glycosylation of fibroblast growth factor receptor 4 is a key
RT   regulator of fibroblast growth factor 19-mediated down-regulation of
RT   cytochrome P450 7A1.";
RL   Hepatology 52:656-666(2010).
RN   [26]
RP   FUNCTION IN HEPATOCYTE PROLIFERATION AND FGF19 SIGNALING.
RX   PubMed=20018895; DOI=10.1074/jbc.M109.068783;
RA   Wu X., Ge H., Lemon B., Vonderfecht S., Weiszmann J., Hecht R.,
RA   Gupte J., Hager T., Wang Z., Lindberg R., Li Y.;
RT   "FGF19-induced hepatocyte proliferation is mediated through FGFR4
RT   activation.";
RL   J. Biol. Chem. 285:5165-5170(2010).
RN   [27]
RP   FUNCTION IN DOWN-REGULATION OF MMP14, AUTOPHOSPHORYLATION, AND
RP   INTERACTION WITH MMP14.
RX   PubMed=20798051; DOI=10.1073/pnas.0914459107;
RA   Sugiyama N., Varjosalo M., Meller P., Lohi J., Chan K.M., Zhou Z.,
RA   Alitalo K., Taipale J., Keski-Oja J., Lehti K.;
RT   "FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a
RT   membrane type 1 matrix metalloproteinase-FGFR4 complex.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:15786-15791(2010).
RN   [28]
RP   INVOLVEMENT IN PC, AND VARIANT PC ARG-388.
RX   PubMed=21349172; DOI=10.1186/1471-2407-11-84;
RA   Xu B., Tong N., Chen S.Q., Hua L.X., Wang Z.J., Zhang Z.D., Chen M.;
RT   "FGFR4 Gly388Arg polymorphism contributes to prostate cancer
RT   development and progression: a meta-analysis of 2618 cases and 2305
RT   controls.";
RL   BMC Cancer 11:84-84(2011).
RN   [29]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [30]
RP   INVOLVEMENT IN CANCER.
RX   PubMed=21412156; DOI=10.1097/CEJ.0b013e3283457274;
RA   Frullanti E., Berking C., Harbeck N., Jezequel P., Haugen A.,
RA   Mawrin C., Parise O. Jr., Sasaki H., Tsuchiya N., Dragani T.A.;
RT   "Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer
RT   prognostic factor.";
RL   Eur. J. Cancer Prev. 20:340-347(2011).
RN   [31]
RP   FUNCTION IN FGF19 SIGNALING, FUNCTION IN STIMULATION OF CELL
RP   PROLIFERATION AND ACTIVATION OF MAPK1/ERK2 AND MAPK3/ERK1, AND
RP   INTERACTION WITH FGF19; KLB AND SULFATED GLYCOSAMINOGLYCANS.
RX   PubMed=21653700; DOI=10.1074/jbc.M111.251140;
RA   Nakamura M., Uehara Y., Asada M., Honda E., Nagai N., Kimata K.,
RA   Suzuki M., Imamura T.;
RT   "Sulfated glycosaminoglycans are required for specific and sensitive
RT   fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and
RT   betaKlotho.";
RL   J. Biol. Chem. 286:26418-26423(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   INTERACTION WITH STAT3, INVOLVEMENT IN CANCER, AND CHARACTERIZATION OF
RP   VARIANT PC ARG-388.
RX   PubMed=26675719; DOI=10.1038/nature16449;
RA   Ulaganathan V.K., Sperl B., Rapp U.R., Ullrich A.;
RT   "Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3
RT   binding site.";
RL   Nature 528:570-574(2015).
RN   [35]
RP   VARIANTS [LARGE SCALE ANALYSIS] ILE-10; LEU-136; ALA-179; SER-426;
RP   ASN-516; MET-550; THR-712 AND ASN-772.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [36]
RP   REVIEW ON LIGAND SELECTIVITY AND SIGNALING.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [37]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [38]
RP   CHARACTERIZATION OF VARIANT PC ARG-388, AND FUNCTION IN TUMOR CELL
RP   INVASION.
RX   PubMed=20876804; DOI=10.1158/0008-5472.CAN-10-1223;
RA   Sugiyama N., Varjosalo M., Meller P., Lohi J., Hyytiainen M.,
RA   Kilpinen S., Kallioniemi O., Ingvarsen S., Engelholm L.H., Taipale J.,
RA   Alitalo K., Keski-Oja J., Lehti K.;
RT   "Fibroblast growth factor receptor 4 regulates tumor invasion by
RT   coupling fibroblast growth factor signaling to extracellular matrix
RT   degradation.";
RL   Cancer Res. 70:7851-7861(2010).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface
CC       receptor for fibroblast growth factors and plays a role in the
CC       regulation of cell proliferation, differentiation and migration,
CC       and in regulation of lipid metabolism, bile acid biosynthesis,
CC       glucose uptake, vitamin D metabolism and phosphate homeostasis.
CC       Required for normal down-regulation of the expression of CYP7A1,
CC       the rate-limiting enzyme in bile acid synthesis, in response to
CC       FGF19. Phosphorylates PLCG1 and FRS2. Ligand binding leads to the
CC       activation of several signaling cascades. Activation of PLCG1
CC       leads to the production of the cellular signaling molecules
CC       diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation
CC       of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and
CC       mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP
CC       kinase signaling pathway, as well as of the AKT1 signaling
CC       pathway. Promotes SRC-dependent phosphorylation of the matrix
CC       protease MMP14 and its lysosomal degradation. FGFR4 signaling is
CC       down-regulated by receptor internalization and degradation; MMP14
CC       promotes internalization and degradation of FGFR4. Mutations that
CC       lead to constitutive kinase activation or impair normal FGFR4
CC       inactivation lead to aberrant signaling.
CC       {ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:18480409, ECO:0000269|PubMed:18670643,
CC       ECO:0000269|PubMed:20018895, ECO:0000269|PubMed:20683963,
CC       ECO:0000269|PubMed:20798051, ECO:0000269|PubMed:20876804,
CC       ECO:0000269|PubMed:21653700, ECO:0000269|PubMed:7518429,
CC       ECO:0000269|PubMed:7680645, ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028, ECO:0000269|PubMed:11433297,
CC       ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:18480409,
CC       ECO:0000269|PubMed:18670643}.
CC   -!- ENZYME REGULATION: Present in an inactive conformation in the
CC       absence of bound ligand. Ligand binding leads to dimerization and
CC       activation by autophosphorylation on tyrosine residues.
CC       {ECO:0000269|PubMed:18480409}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with
CC       FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, FGF16, FGF17, FGF18, FGF19,
CC       FGF21 and FGF23 (in vitro). Binding affinity for FGF family
CC       members is enhanced by interactions between FGFs and heparan
CC       sulfate proteoglycans. Interacts with KLB; this strongly increases
CC       the affinity for FGF19 and FGF23. Affinity for FGF19 is strongly
CC       increased by KLB and sulfated glycosaminoglycans. KLB and KL both
CC       interact with the core-glycosylated FGFR4 in the endoplasmic
CC       reticulum and promote its degradation, so that only FGFR4 with
CC       fully mature N-glycans is expressed at the cell surface.
CC       Identified in a complex with NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1,
CC       GAP43 and CTTN. Interacts with MMP14 and HIP1 (PubMed:11433297,
CC       PubMed:16597617, PubMed:17623664, PubMed:18670643,
CC       PubMed:20683963, PubMed:20798051, PubMed:21653700, PubMed:7518429,
CC       PubMed:8663044). Interacts with STAT3 (PubMed:26675719).
CC       {ECO:0000269|PubMed:11433297, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17623664, ECO:0000269|PubMed:18670643,
CC       ECO:0000269|PubMed:20683963, ECO:0000269|PubMed:20798051,
CC       ECO:0000269|PubMed:21653700, ECO:0000269|PubMed:26675719,
CC       ECO:0000269|PubMed:7518429, ECO:0000269|PubMed:8663044}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Single-pass type I membrane
CC       protein. Endosome. Endoplasmic reticulum. Note=Internalized from
CC       the cell membrane to recycling endosomes, and from there back to
CC       the cell membrane.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Secreted.
CC   -!- SUBCELLULAR LOCATION: Isoform 3: Cytoplasm
CC       {ECO:0000269|PubMed:11781352}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P22455-1; Sequence=Displayed;
CC       Name=2; Synonyms=Soluble-form;
CC         IsoId=P22455-2; Sequence=VSP_035108;
CC       Name=3;
CC         IsoId=P22455-3; Sequence=VSP_053542;
CC         Note=Lacks a signal peptide. Constitutively phosphorylated.;
CC   -!- TISSUE SPECIFICITY: Expressed in gastrointestinal epithelial
CC       cells, pancreas, and gastric and pancreatic cancer cell lines.
CC       {ECO:0000269|PubMed:10631118}.
CC   -!- PTM: N-glycosylated. Full maturation of the glycan chains in the
CC       Golgi is essential for high affinity interaction with FGF19.
CC   -!- PTM: Ubiquitinated. Subject to proteasomal degradation when not
CC       fully glycosylated. {ECO:0000269|PubMed:18480409}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together
CC       with heparan sulfate proteoglycan or heparin promotes receptor
CC       dimerization and autophosphorylation on tyrosine residues.
CC       Autophosphorylation occurs in trans between the two FGFR molecules
CC       present in the dimer. {ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:7518429}.
CC   -!- DISEASE: Prostate cancer (PC) [MIM:176807]: A malignancy
CC       originating in tissues of the prostate. Most prostate cancers are
CC       adenocarcinomas that develop in the acini of the prostatic ducts.
CC       Other rare histopathologic types of prostate cancer that occur in
CC       approximately 5% of patients include small cell carcinoma,
CC       mucinous carcinoma, prostatic ductal carcinoma, transitional cell
CC       carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid
CC       cystic carcinoma (basaloid), signet-ring cell carcinoma and
CC       neuroendocrine carcinoma. {ECO:0000269|PubMed:18670643,
CC       ECO:0000269|PubMed:18756523, ECO:0000269|PubMed:20876804,
CC       ECO:0000269|PubMed:21349172}. Note=The gene represented in this
CC       entry is involved in disease pathogenesis. FGFR4 variant Arg-388
CC       has been associated with prostate cancer as well as cancers of the
CC       breast, colon, head and neck, larynx, lung, skin. Arg-388
CC       predisposes cancer patients for accelerated disease progression
CC       and is associated with poor prognosis.
CC       {ECO:0000269|PubMed:11781352, ECO:0000269|PubMed:11830541,
CC       ECO:0000269|PubMed:18670643, ECO:0000269|PubMed:18756523,
CC       ECO:0000269|PubMed:20638838, ECO:0000269|PubMed:20876804,
CC       ECO:0000269|PubMed:21349172, ECO:0000269|PubMed:21412156,
CC       ECO:0000269|PubMed:21882254, ECO:0000269|PubMed:26675719}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr4/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFR4ID512ch5q35.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X57205; CAA40490.1; -; mRNA.
DR   EMBL; L03840; AAB59389.1; -; mRNA.
DR   EMBL; AF202063; AAF27432.1; -; mRNA.
DR   EMBL; Y13901; CAA74200.1; -; Genomic_DNA.
DR   EMBL; AF359246; AAK51435.1; -; mRNA.
DR   EMBL; JN007471; AEO19712.1; -; mRNA.
DR   EMBL; JN007472; AEO19713.1; -; mRNA.
DR   EMBL; JN007473; AEO19714.1; -; mRNA.
DR   EMBL; JN007474; AEO19715.1; -; mRNA.
DR   EMBL; JN007475; AEO19716.1; -; mRNA.
DR   EMBL; JN007476; AEO19717.1; -; mRNA.
DR   EMBL; JN007477; AEO19718.1; -; mRNA.
DR   EMBL; JN007478; AEO19719.1; -; mRNA.
DR   EMBL; JN007479; AEO19720.1; -; mRNA.
DR   EMBL; JN007480; AEO19721.1; -; mRNA.
DR   EMBL; JN007481; AEO19722.1; -; mRNA.
DR   EMBL; JN007482; AEO19723.1; -; mRNA.
DR   EMBL; AF487555; AAM13666.1; -; Genomic_DNA.
DR   EMBL; EF571596; ABQ01235.1; -; Genomic_DNA.
DR   EMBL; AC027314; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471195; EAW85036.1; -; Genomic_DNA.
DR   EMBL; BC011847; AAH11847.1; -; mRNA.
DR   EMBL; M59373; AAA63208.1; -; mRNA.
DR   CCDS; CCDS4410.1; -. [P22455-1]
DR   CCDS; CCDS4411.1; -. [P22455-2]
DR   PIR; S15345; TVHUF4.
DR   RefSeq; NP_001278909.1; NM_001291980.1.
DR   RefSeq; NP_002002.3; NM_002011.4. [P22455-1]
DR   RefSeq; NP_075252.2; NM_022963.3. [P22455-2]
DR   RefSeq; NP_998812.1; NM_213647.2. [P22455-1]
DR   RefSeq; XP_005265895.1; XM_005265838.3. [P22455-1]
DR   UniGene; Hs.165950; -.
DR   PDB; 1QCT; Model; -; B/E=36-353.
DR   PDB; 4QQ5; X-ray; 2.20 A; A=445-753.
DR   PDB; 4QQC; X-ray; 2.40 A; A=445-753.
DR   PDB; 4QQJ; X-ray; 1.68 A; A=445-753.
DR   PDB; 4QQT; X-ray; 1.50 A; A=445-753.
DR   PDB; 4QRC; X-ray; 1.90 A; A=445-753.
DR   PDB; 4R6V; X-ray; 2.35 A; A=445-753.
DR   PDB; 4TYE; X-ray; 2.80 A; A=447-753.
DR   PDB; 4TYG; X-ray; 2.40 A; A=447-753.
DR   PDB; 4TYI; X-ray; 3.40 A; A=447-753.
DR   PDB; 4TYJ; X-ray; 2.45 A; A=447-753.
DR   PDB; 4UXQ; X-ray; 1.85 A; A=447-753.
DR   PDB; 4XCU; X-ray; 1.71 A; A=449-751.
DR   PDB; 5JKG; X-ray; 2.35 A; A=445-753.
DR   PDBsum; 1QCT; -.
DR   PDBsum; 4QQ5; -.
DR   PDBsum; 4QQC; -.
DR   PDBsum; 4QQJ; -.
DR   PDBsum; 4QQT; -.
DR   PDBsum; 4QRC; -.
DR   PDBsum; 4R6V; -.
DR   PDBsum; 4TYE; -.
DR   PDBsum; 4TYG; -.
DR   PDBsum; 4TYI; -.
DR   PDBsum; 4TYJ; -.
DR   PDBsum; 4UXQ; -.
DR   PDBsum; 4XCU; -.
DR   PDBsum; 5JKG; -.
DR   ProteinModelPortal; P22455; -.
DR   SMR; P22455; -.
DR   BioGrid; 108555; 31.
DR   DIP; DIP-5149N; -.
DR   IntAct; P22455; 23.
DR   STRING; 9606.ENSP00000292408; -.
DR   BindingDB; P22455; -.
DR   ChEMBL; CHEMBL3973; -.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB00039; Palifermin.
DR   DrugBank; DB08901; Ponatinib.
DR   GuidetoPHARMACOLOGY; 1811; -.
DR   iPTMnet; P22455; -.
DR   PhosphoSitePlus; P22455; -.
DR   BioMuta; FGFR4; -.
DR   DMDM; 13432140; -.
DR   MaxQB; P22455; -.
DR   PaxDb; P22455; -.
DR   PeptideAtlas; P22455; -.
DR   PRIDE; P22455; -.
DR   DNASU; 2264; -.
DR   Ensembl; ENST00000292408; ENSP00000292408; ENSG00000160867. [P22455-1]
DR   Ensembl; ENST00000393637; ENSP00000377254; ENSG00000160867. [P22455-2]
DR   Ensembl; ENST00000502906; ENSP00000424960; ENSG00000160867. [P22455-1]
DR   GeneID; 2264; -.
DR   KEGG; hsa:2264; -.
DR   UCSC; uc003mfl.4; human. [P22455-1]
DR   CTD; 2264; -.
DR   DisGeNET; 2264; -.
DR   GeneCards; FGFR4; -.
DR   HGNC; HGNC:3691; FGFR4.
DR   HPA; CAB005196; -.
DR   HPA; HPA027273; -.
DR   HPA; HPA027369; -.
DR   HPA; HPA028251; -.
DR   MalaCards; FGFR4; -.
DR   MIM; 134935; gene.
DR   MIM; 176807; phenotype.
DR   neXtProt; NX_P22455; -.
DR   OpenTargets; ENSG00000160867; -.
DR   PharmGKB; PA28130; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118923; -.
DR   HOGENOM; HOG000263410; -.
DR   HOVERGEN; HBG000345; -.
DR   InParanoid; P22455; -.
DR   KO; K05095; -.
DR   OMA; QDFHGEH; -.
DR   OrthoDB; EOG091G0CQZ; -.
DR   PhylomeDB; P22455; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1307965; betaKlotho-mediated ligand binding.
DR   Reactome; R-HSA-1839128; FGFR4 mutant receptor activation.
DR   Reactome; R-HSA-190322; FGFR4 ligand binding and activation.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654228; Phospholipase C-mediated cascade, FGFR4.
DR   Reactome; R-HSA-5654712; FRS-mediated FGFR4 signaling.
DR   Reactome; R-HSA-5654719; SHC-mediated cascade:FGFR4.
DR   Reactome; R-HSA-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-HSA-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-HSA-5655291; Signaling by FGFR4 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   SIGNOR; P22455; -.
DR   ChiTaRS; FGFR4; human.
DR   GeneWiki; Fibroblast_growth_factor_receptor_4; -.
DR   GenomeRNAi; 2264; -.
DR   PRO; PR:P22455; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000160867; -.
DR   CleanEx; HS_FGFR4; -.
DR   ExpressionAtlas; P22455; baseline and differential.
DR   Genevisible; P22455; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030133; C:transport vesicle; IDA:UniProtKB.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor-activated receptor activity; IDA:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; IDA:UniProtKB.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; TAS:Reactome.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:Reactome.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0055062; P:phosphate ion homeostasis; ISS:UniProtKB.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0043085; P:positive regulation of catalytic activity; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000573; P:positive regulation of DNA biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0045862; P:positive regulation of proteolysis; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0070857; P:regulation of bile acid biosynthetic process; IMP:UniProtKB.
DR   GO; GO:2000188; P:regulation of cholesterol homeostasis; ISS:UniProtKB.
DR   GO; GO:0010715; P:regulation of extracellular matrix disassembly; IMP:UniProtKB.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; ISS:UniProtKB.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; Endoplasmic reticulum; Endosome;
KW   Glycoprotein; Immunoglobulin domain; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Secreted; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     21       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        22    802       Fibroblast growth factor receptor 4.
FT                                /FTId=PRO_0000016787.
FT   TOPO_DOM     22    369       Extracellular. {ECO:0000255}.
FT   TRANSMEM    370    390       Helical. {ECO:0000255}.
FT   TOPO_DOM    391    802       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       22    118       Ig-like C2-type 1.
FT   DOMAIN      152    240       Ig-like C2-type 2.
FT   DOMAIN      249    349       Ig-like C2-type 3.
FT   DOMAIN      467    755       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     473    481       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    612    612       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     503    503       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     573    573       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     642    642       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18670643}.
FT   MOD_RES     643    643       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18670643}.
FT   MOD_RES     754    754       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:7518429}.
FT   CARBOHYD    112    112       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    258    258       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    290    290       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    311    311       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    322    322       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     57    101       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    172    224       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    271    333       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1    210       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:11781352}.
FT                                /FTId=VSP_053542.
FT   VAR_SEQ     353    416       EEDPTWTAAAPEARYTDIILYASGSLALAVLLLLAGLYRGQ
FT                                ALHGRHPRPPATVQKLSRFPLAR -> GTGRIPHLTCDSLT
FT                                PAGRTKSPTL (in isoform 2).
FT                                {ECO:0000303|PubMed:10631118}.
FT                                /FTId=VSP_035108.
FT   VARIANT      10     10       V -> I (in dbSNP:rs1966265).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21882254,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_029185.
FT   VARIANT     136    136       P -> L (in dbSNP:rs376618).
FT                                {ECO:0000269|PubMed:10631118,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:21882254,
FT                                ECO:0000269|Ref.10, ECO:0000269|Ref.7,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_042211.
FT   VARIANT     179    179       T -> A (in dbSNP:rs55675160).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042212.
FT   VARIANT     388    388       G -> R (in PC; also found in other types
FT                                of cancer; associated with increased
FT                                disease susceptibility, accelerated
FT                                cancer progression and poor prognosis;
FT                                results in prolonged FGFR4 activity;
FT                                causes increased cell motility and tumor
FT                                cell invasion possibly due to increased
FT                                stability of the protease MMP14;
FT                                increased interaction with STAT3; results
FT                                in STAT3 phosphorylation and signaling
FT                                activation; dbSNP:rs351855).
FT                                {ECO:0000269|PubMed:11781352,
FT                                ECO:0000269|PubMed:18670643,
FT                                ECO:0000269|PubMed:18756523,
FT                                ECO:0000269|PubMed:20876804,
FT                                ECO:0000269|PubMed:21349172,
FT                                ECO:0000269|PubMed:21882254,
FT                                ECO:0000269|PubMed:26675719,
FT                                ECO:0000269|Ref.8}.
FT                                /FTId=VAR_014797.
FT   VARIANT     426    426       G -> S (in dbSNP:rs55879131).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046102.
FT   VARIANT     516    516       D -> N (in dbSNP:rs34158682).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042213.
FT   VARIANT     529    529       R -> Q (in dbSNP:rs34284947).
FT                                /FTId=VAR_049720.
FT   VARIANT     550    550       V -> M (in breast pleomorphic lobular
FT                                sample; somatic mutation;
FT                                dbSNP:rs774571806).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046103.
FT   VARIANT     712    712       P -> T (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046104.
FT   VARIANT     772    772       S -> N (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046105.
FT   MUTAGEN     503    503       K->R: Loss of kinase activity.
FT                                {ECO:0000269|PubMed:11433297,
FT                                ECO:0000269|PubMed:17311277}.
FT   MUTAGEN     754    754       Y->F: Loss of interaction with PLCG1.
FT                                {ECO:0000269|PubMed:7518429}.
FT   CONFLICT    121    121       L -> S (in Ref. 3; AAF27432).
FT                                {ECO:0000305}.
FT   CONFLICT    194    194       E -> G (in Ref. 3; AAF27432).
FT                                {ECO:0000305}.
FT   CONFLICT    297    297       D -> V (in Ref. 1; CAA40490).
FT                                {ECO:0000305}.
FT   HELIX       445    448       {ECO:0000244|PDB:4QQ5}.
FT   TURN        458    460       {ECO:0000244|PDB:4QQT}.
FT   HELIX       464    466       {ECO:0000244|PDB:4QQT}.
FT   STRAND      467    474       {ECO:0000244|PDB:4QQT}.
FT   STRAND      480    487       {ECO:0000244|PDB:4QQT}.
FT   STRAND      493    495       {ECO:0000244|PDB:5JKG}.
FT   STRAND      497    504       {ECO:0000244|PDB:4QQT}.
FT   HELIX       511    527       {ECO:0000244|PDB:4QQT}.
FT   STRAND      536    540       {ECO:0000244|PDB:4QQT}.
FT   STRAND      542    544       {ECO:0000244|PDB:4QQT}.
FT   STRAND      547    551       {ECO:0000244|PDB:4QQT}.
FT   HELIX       558    563       {ECO:0000244|PDB:4QQT}.
FT   STRAND      572    574       {ECO:0000244|PDB:4TYE}.
FT   HELIX       586    605       {ECO:0000244|PDB:4QQT}.
FT   HELIX       615    617       {ECO:0000244|PDB:4QQT}.
FT   STRAND      618    620       {ECO:0000244|PDB:4QQT}.
FT   STRAND      626    628       {ECO:0000244|PDB:4QQT}.
FT   TURN        631    635       {ECO:0000244|PDB:4XCU}.
FT   HELIX       637    639       {ECO:0000244|PDB:4QQT}.
FT   STRAND      642    644       {ECO:0000244|PDB:4UXQ}.
FT   HELIX       652    655       {ECO:0000244|PDB:4QQT}.
FT   HELIX       658    663       {ECO:0000244|PDB:4QQT}.
FT   HELIX       668    683       {ECO:0000244|PDB:4QQT}.
FT   STRAND      689    692       {ECO:0000244|PDB:4TYJ}.
FT   HELIX       695    703       {ECO:0000244|PDB:4QQT}.
FT   HELIX       716    725       {ECO:0000244|PDB:4QQT}.
FT   HELIX       730    732       {ECO:0000244|PDB:4QQT}.
FT   HELIX       736    748       {ECO:0000244|PDB:4QQT}.
SQ   SEQUENCE   802 AA;  87954 MW;  B22B259831BB889F CRC64;
     MRLLLALLGV LLSVPGPPVL SLEASEEVEL EPCLAPSLEQ QEQELTVALG QPVRLCCGRA
     ERGGHWYKEG SRLAPAGRVR GWRGRLEIAS FLPEDAGRYL CLARGSMIVL QNLTLITGDS
     LTSSNDDEDP KSHRDPSNRH SYPQQAPYWT HPQRMEKKLH AVPAGNTVKF RCPAAGNPTP
     TIRWLKDGQA FHGENRIGGI RLRHQHWSLV MESVVPSDRG TYTCLVENAV GSIRYNYLLD
     VLERSPHRPI LQAGLPANTT AVVGSDVELL CKVYSDAQPH IQWLKHIVIN GSSFGADGFP
     YVQVLKTADI NSSEVEVLYL RNVSAEDAGE YTCLAGNSIG LSYQSAWLTV LPEEDPTWTA
     AAPEARYTDI ILYASGSLAL AVLLLLAGLY RGQALHGRHP RPPATVQKLS RFPLARQFSL
     ESGSSGKSSS SLVRGVRLSS SGPALLAGLV SLDLPLDPLW EFPRDRLVLG KPLGEGCFGQ
     VVRAEAFGMD PARPDQASTV AVKMLKDNAS DKDLADLVSE MEVMKLIGRH KNIINLLGVC
     TQEGPLYVIV ECAAKGNLRE FLRARRPPGP DLSPDGPRSS EGPLSFPVLV SCAYQVARGM
     QYLESRKCIH RDLAARNVLV TEDNVMKIAD FGLARGVHHI DYYKKTSNGR LPVKWMAPEA
     LFDRVYTHQS DVWSFGILLW EIFTLGGSPY PGIPVEELFS LLREGHRMDR PPHCPPELYG
     LMRECWHAAP SQRPTFKQLV EALDKVLLAV SEEYLDLRLT FGPYSPSGGD ASSTCSSSDS
     VFSHDPLPLG SSSFPFGSGV QT
//
